2-Hydroxyglutarate concentration in serum from patients with gliomas does not correlate with IDH1/2 mutation status or tumor size. - Wikidata - wikimedia - TriplyDB

2-Hydroxyglutarate concentration in serum from patients with gliomas does not correlate with IDH1/2 mutation status or tumor size.

2-Hydroxyglutarate concentration in serum from patients with gliomas does not correlate with IDH1/2 mutation status or tumor size.

http://www.wikidata.org/entity/Q47355822

about

Genetics and Epigenetics of Glioblastoma: Applications and Overall Incidence of IDH1 Mutation Circulating glioma biomarkers IDH1/2 mutations target a key hallmark of cancer by deregulating cellular metabolism in glioma IDH mutations in tumorigenesis and their potential role as novel therapeutic targets.IDH1 and IDH2 mutations as novel therapeutic targets: current perspectives Isocitrate dehydrogenase 1 (IDH1) mutation in breast adenocarcinoma is associated with elevated levels of serum and urine 2-hydroxyglutarate.Circulating oncometabolite 2-hydroxyglutarate is a potential surrogate biomarker in patients with isocitrate dehydrogenase-mutant intrahepatic cholangiocarcinoma.Decreased 5-hydroxymethylcytosine is associated with neural progenitor phenotype in normal brain and shorter survival in malignant glioma.Diagnostic value of plasma and urinary 2-hydroxyglutarate to identify patients with isocitrate dehydrogenase-mutated glioma.Emerging insights into the molecular and cellular basis of glioblastoma.Discordant intracellular and plasma D-2-hydroxyglutarate levels in a patient with IDH2 mutated angioimmunoblastic T-cell lymphoma Personalized care in neuro-oncology coming of age: why we need MGMT and 1p/19q testing for malignant glioma patients in clinical practice.Integration of 2-hydroxyglutarate-proton magnetic resonance spectroscopy into clinical practice for disease monitoring in isocitrate dehydrogenase-mutant glioma.Elevation of Urinary 2-Hydroxyglutarate in IDH-Mutant Glioma Quantitative Imaging of D-2-Hydroxyglutarate in Selected Histological Tissue Areas by a Novel Bioluminescence Technique.What do we know about IDH1/2 mutations so far, and how do we use it?Accumulation of 2-hydroxyglutarate is not a biomarker for malignant progression in IDH-mutated low-grade gliomas Metabolomics profiling in plasma samples from glioma patients correlates with tumor phenotypes.Prognostic significance of 2-hydroxyglutarate levels in acute myeloid leukemia in China.Increased mitochondrial activity in a novel IDH1-R132H mutant human oligodendroglioma xenograft model: in situ detection of 2-HG and α-KG.Circulating biomarkers of CNS tumors: an update.Liquid biopsies in patients with diffuse glioma.Study protocol of a phase IB/II clinical trial of metformin and chloroquine in patients with IDH1-mutated or IDH2-mutated solid tumours Circulating biomarkers for gliomas.Emerging circulating biomarkers in glioblastoma: promises and challenges.Driver mutations of cancer epigenomes.HOT mutation screening in human glioblastomas.Mechanisms underlying the biological changes induced by isocitrate dehydrogenase-1 mutation in glioma cells.Mutant IDH1 and thrombosis in gliomas.An in vivo patient-derived model of endogenous IDH1-mutant glioma.BEAMing and Droplet Digital PCR Analysis of Mutant IDH1 mRNA in Glioma Patient Serum and Cerebrospinal Fluid Extracellular Vesicles.The Role of Mitochondrial NADPH-Dependent Isocitrate Dehydrogenase in Cancer Cells.Selective Detection of the D-enantiomer of 2-Hydroxyglutarate in the CSF of Glioma Patients with Mutated Isocitrate Dehydrogenase.A prospective study of serum metabolites and glioma risk.Can diffusion tensor imaging noninvasively detect IDH1 gene mutations in astrogliomas? A retrospective study of 112 cases.MicroRNA in Glioblastoma: An Overview.In vivo Metabolic Profiles as Determined by (31)P and short TE (1)H MR-Spectroscopy : No Difference Between Patients with IDH Wildtype and IDH Mutant Gliomas.Beyond Brooding on Oncometabolic Havoc in IDH-Mutant Gliomas and AML: Current and Future Therapeutic Strategies.Focused Ultrasound-enabled Brain Tumor Liquid Biopsy.Pharmacodynamics of mutant-IDH1 inhibitors in glioma patients probed by in vivo 3D MRS imaging of 2-hydroxyglutarate.

P2860

Q26767392-7ED33BD2-82EE-469E-BADE-BC1EF31AB237 Q26830329-9766D514-F3A7-4AC4-B9B5-48E4B03F2D69 Q26995506-E4C6E55C-43DE-4B30-9A1C-80F33B1C83D9 Q27692015-FFA54CF6-A360-461C-B1DE-3554543944AA Q28066926-88EE0C4A-76D1-4515-82E3-413D90F56547 Q33699608-481E251E-2DDD-4B59-BEB2-C1AA74374F2A Q33936179-06F8140E-E9B4-4223-B9C7-555E21890BB0 Q34351124-37C47A1A-937F-4C6A-B2D1-A41F2597F53C Q35586677-1CA3836E-2666-4203-86D8-063416E9415A Q35914897-BE2EF730-C19B-4373-AF88-1A336FECD6F2 Q36262067-4E37FB18-DCF8-4C81-A737-F49A125BB275 Q36344709-C2B3B7B4-0742-4B42-9D83-06BB9B5E77A0 Q36493858-C049CA6A-A5F5-47D0-B41F-60429805B8BE Q36558431-6D307920-EB41-4309-979F-07F9A3847AC3 Q36656510-DE026077-23A7-4CA8-B43E-D453C4EB102B Q36788229-52697709-7A1A-4485-9AAC-1478F72A432B Q36865995-F82D1F05-62AA-40DA-AE43-66F1C4878F4F Q37190344-9D660D68-BDFB-4699-945C-AB6DD85B6CE5 Q37240701-208A982D-B9D5-45E2-B261-3720633CA48D Q37485784-10AB682C-0E04-47EE-943E-DD6CDA7A11B8 Q38095109-8D6F42FE-5241-4CDE-A9E0-5368306DB01D Q38365590-7143B139-8133-4E42-871C-41FE885E8119 Q38375735-440AF17B-DCE1-459E-BC99-BA541D8F0D8D Q38586617-A39A7933-0D76-403F-BD1E-0EBED3AF2FAC Q38591062-CE47CBFC-0A45-4662-9294-749C963B675E Q38639828-4B53F9A4-6A53-4729-B329-02CE65B18120 Q38747962-FDB1B5CC-B502-4509-AA60-3FF05D97F2F2 Q39024621-830A511F-A889-4187-BEEE-221BBA4205BE Q39355644-5C9AD1B6-F4D5-426E-AF48-8887735E1C27 Q39429029-2E9058CD-5030-4D84-8208-33DF95441A0B Q40126434-520564D0-D2C6-453D-AA7D-9FFB6BE91F42 Q41859976-5A707829-4C56-4331-8D06-A68A3E6350CF Q42246513-C4476F9A-8F30-44B7-9B4F-1AF3C698DBA8 Q42378435-5C055D8D-03C9-43E1-BE4E-884C170E051F Q46104308-28DD3979-AFBF-4E86-B703-C3013536EE10 Q47142132-A30AD404-3EEF-47F7-AF13-EBAE539F72F8 Q47853442-10968ADF-C88C-458E-8277-237701D5C865 Q50033966-01FCD8F4-D60C-41C6-A746-3B0AC63C2161 Q52560196-11CBC2D6-4670-438C-8EA1-06CAE3F8648C Q52584624-15F4069C-D9F0-494C-85B3-E889D981BECD

P2860

2-Hydroxyglutarate concentration in serum from patients with gliomas does not correlate with IDH1/2 mutation status or tumor size.

http://www.wikidata.org/entity/Q47355822

description

2011 nî lūn-bûn

@nan

2011年の論文

@ja

2011年学术文章

@wuu

2011年学术文章

@zh

2011年学术文章

@zh-cn

2011年学术文章

@zh-hans

2011年学术文章

@zh-my

2011年学术文章

@zh-sg

2011年學術文章

@yue

2011年學術文章

@zh-hant

name

2-Hydroxyglutarate concentrati ...... mutation status or tumor size.

@en

2-Hydroxyglutarate concentrati ...... mutation status or tumor size.

@nl

type

label

2-Hydroxyglutarate concentrati ...... mutation status or tumor size.

@en

2-Hydroxyglutarate concentrati ...... mutation status or tumor size.

@nl

prefLabel

2-Hydroxyglutarate concentrati ...... mutation status or tumor size.

@en

2-Hydroxyglutarate concentrati ...... mutation status or tumor size.

@nl

P1433

Q47355822-CD308D6B-2BC3-40FC-B2E6-7B353D122D1F

P1476

Q47355822-29159577-E64B-4846-A2CA-D86AAD19B96A

P2093

Q47355822-02CFC96D-B38E-47E5-A9A1-8FE502F1C5A0

Q47355822-2245B09C-5775-4BB3-BEE3-BF0C9B53D649

Q47355822-303A563A-76E4-4EC0-9609-1A6E604881C0

Q47355822-314BB45C-3D6C-407C-AB56-E9CF90296CC2

Q47355822-80F875A3-B56B-4834-867D-AEEA6F9BD261

Q47355822-FFF00234-9C7B-405D-8E64-FADDA8C9D0F2

P304

Q47355822-03BB3283-4424-4529-9A96-10F215F7EF2D

P31

Q47355822-1830B35C-D9E9-446F-9ED2-5425B25250DA

P356

Q47355822-F3A71094-84A2-4388-9EC6-2106415796EE

P433

Q47355822-2FBCDF0E-E0C6-4CDA-B7F6-197C71555013

P478

Q47355822-C1A9AAE8-AE3F-43BF-9D71-C3C9D8D1E790

P50

Q47355822-13CFB6A7-1CBC-4464-B6E1-5B0149A33C62

Q47355822-569CD7B1-A8CE-4233-AD96-BFA2C25B88FA

Q47355822-BAA70CB8-8E3D-4A09-B78C-C2A70A7F3EB9

P577

Q47355822-603F0DCE-9166-468D-A5E2-BBF5AC83A8E7

P5875

Q47355822-54BC9C97-AF8E-40E8-8C83-84DEDD819048

P698

Q47355822-484FEDD9-16F1-423B-9FEC-E1FAEE80E5F7

P356

P1433

International Journal of Cancer

P1476

2-Hydroxyglutarate concentrati ...... mutation status or tumor size.

@en

P2093

Christian Hartmann

http://www.w3.org/2001/XMLSchema#string

Claus-Dieter Langhans

http://www.w3.org/2001/XMLSchema#string

German Glioma Network

http://www.w3.org/2001/XMLSchema#string

Jörg C Tonn

http://www.w3.org/2001/XMLSchema#string

Jürgen G Okun

http://www.w3.org/2001/XMLSchema#string

Matthias Simon

http://www.w3.org/2001/XMLSchema#string

P304

766-768

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/IJC.26425

http://www.w3.org/2001/XMLSchema#string

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

131

http://www.w3.org/2001/XMLSchema#string

P50

Andreas von Deimling

P577

2011-11-02T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

51633276

http://www.w3.org/2001/XMLSchema#string

P698

21913188

http://www.w3.org/2001/XMLSchema#string